Background

Low-skeletal muscle mass (LSMM) is defined as progressive skeletal muscle loss, which can be assessed by imaging modalities. It was shown that this parameter is predictive and prognostic of several clinically relevant factors in several tumor entities. Our aim was to establish the effect of LSMM on overall survival (OS) in prostate cancer patients based on a large patient sample.

Methods

MEDLINE library, EMBASE and SCOPUS databases were screened for the associations between LSMM and mortality in prostate cancer patients up to April 2021. The primary endpoint of the systematic review was the hazard ratio of LSMM on OS. In total, five studies were suitable for the analysis and included into the present study.

Results

The included studies comprised over all 1221 patients. The identified frequency of LSMM was 61.02%. The pooled hazard ratio for the effect of LSMM on OS was 1.4 [95% CI 0.7-2.5] in univariate analysis and was 1.6 [95% CI 1.2-2.1] in multivariate analysis.

Conclusion

CT-defined LSMM has a frequency of 61% in patients with PC and shows a positive association with the overall survival with a hazard ratio of 1.4. LSMM assessment should therefore be included into clinical routine as a relevant prognostic biomarker.

中文翻译：

---

CT 定义的低骨骼肌质量作为前列腺癌生存的预后标志物：系统评价和荟萃分析

背景

低骨骼肌质量 (LSMM) 被定义为进行性骨骼肌损失，可以通过成像方式进行评估。结果表明，该参数对几种肿瘤实体中的几种临床相关因素具有预测性和预后作用。我们的目的是基于大量患者样本确定 LSMM 对前列腺癌患者总生存期 (OS) 的影响。

方法

MEDLINE 图书馆、EMBASE 和 SCOPUS 数据库筛选了截至 2021 年 4 月 LSMM 与前列腺癌患者死亡率之间的关联。系统评价的主要终点是 LSMM 对 OS 的风险比。总共有五项研究适合分析并纳入本研究。

结果

纳入的研究包括所有 1221 名患者。LSMM的识别频率为61.02%。LSMM 对 OS 影响的汇总风险比在单变量分析中为 1.4 [95% CI 0.7-2.5]，在多变量分析中为 1.6 [95% CI 1.2-2.1]。

结论

CT 定义的 LSMM 在 PC 患者中的频率为 61%，并且与总生存期呈正相关，风险比为 1.4。因此，LSMM 评估应作为相关的预后生物标志物纳入临床常规。